The article addresses Medtronic’s recent FDA approval of the Guardian™ Connect Continuous Glucose Monitoring (CGM) system. A brief overview of all the clinical studies related to CGM has been presented.

It also analyzes the recent findings on a microneedle system for non-invasive insulin delivery. A birds-eye view of patent filings related to microneedles for insulin delivery, with a focus on global players is presented.